Literature DB >> 25804872

Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.

Mark J Ernsting1, Bryan Hoang2, Ines Lohse3, Elijus Undzys2, Pinjiang Cao3, Trevor Do4, Bethany Gill3, Melania Pintilie3, David Hedley5, Shyh-Dar Li6.   

Abstract

Pancreatic ductal adenocarcinomas are characterized by the desmoplastic reaction, a dense fibrous stroma that has been shown to be supportive of tumor cell growth, invasion, and metastasis, and has been associated with resistance to chemotherapy and reduced patient survival. Here, we investigated targeted depletion of stroma for pancreatic cancer therapy via taxane nanoparticles. Cellax-DTX polymer is a conjugate of docetaxel (DTX), polyethylene glycol (PEG), and acetylated carboxymethylcellulose, a construct which condenses into well-defined 120nm particles in an aqueous solution, and is suitable for intravenous injection. We examined Cellax-DTX treatment effects in highly stromal primary patient-derived pancreatic cancer xenografts and in a metastatic PAN02 mouse model of pancreatic cancer, focusing on specific cellular interactions in the stroma, pancreatic tumor growth and metastasis. Greater than 90% of Cellax-DTX particles accumulate in smooth muscle actin (SMA) positive cancer-associated fibroblasts which results in long-term depletion of this stromal cell population, an effect not observed with Nab-paclitaxel (Nab-PTX). The reduction in stromal density leads to a >10-fold increase in tumor perfusion, reduced tumor weight and a reduction in metastasis. Consentingly, Cellax-DTX treatment increased survival when compared to treatment with gemcitabine or Nab-PTX in a metastatic PAN02 mouse model. Cellax-DTX nanoparticles interact with the tumor-associated stroma, selectively interacting with and depleting SMA positive cells and macrophage, effects of which are associated with significant changes in tumor progression and metastasis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Nanoparticles; Pancreatic cancer; Tumor-associated stroma

Mesh:

Substances:

Year:  2015        PMID: 25804872      PMCID: PMC4409566          DOI: 10.1016/j.jconrel.2015.03.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  36 in total

1.  Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein.

Authors:  S M Vogel; R D Minshall; M Pilipović; C Tiruppathi; A B Malik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-12       Impact factor: 5.464

Review 2.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 3.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

4.  Cancer associated fibroblasts: the dark side of the coin.

Authors:  Paolo Cirri; Paola Chiarugi
Journal:  Am J Cancer Res       Date:  2011-03-12       Impact factor: 6.166

5.  Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?

Authors:  Man Yu; Ian F Tannock
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 7.  Friends or foes - bipolar effects of the tumour stroma in cancer.

Authors:  Margareta M Mueller; Norbert E Fusenig
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

8.  Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Authors:  Qing Chang; Mark S Chapman; Jeffrey N Miner; David W Hedley
Journal:  BMC Cancer       Date:  2010-09-28       Impact factor: 4.430

Review 9.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

10.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Authors:  Kristopher K Frese; Albrecht Neesse; Natalie Cook; Tashinga E Bapiro; Martijn P Lolkema; Duncan I Jodrell; David A Tuveson
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

View more
  35 in total

Review 1.  Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.

Authors:  Huan Meng; Andre E Nel
Journal:  Adv Drug Deliv Rev       Date:  2018-06-26       Impact factor: 15.470

2.  Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.

Authors:  Saud A Almawash; Goutam Mondal; Ram I Mahato
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

3.  Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle.

Authors:  Aniruddha Roy; Yucheng Zhao; Yang Yang; Andras Szeitz; Tara Klassen; Shyh-Dar Li
Journal:  Biomaterials       Date:  2017-05-11       Impact factor: 12.479

Review 4.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

Review 5.  Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.

Authors:  Quoc-Viet Le; Juhan Suh; Yu-Kyoung Oh
Journal:  AAPS J       Date:  2019-05-17       Impact factor: 4.009

Review 6.  Current Update of a Carboxymethylcellulose-PEG Conjugate Platform for Delivery of Insoluble Cytotoxic Agents to Tumors.

Authors:  Yang Yang; Joseph Bteich; Shyh-Dar Li
Journal:  AAPS J       Date:  2016-11-21       Impact factor: 4.009

7.  Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.

Authors:  Veronika Schmitt; Claudia Kesch; John K Jackson; Samir Bidnur; Eliana Beraldi; Virginia Yago; Mary Bowden; Martin E Gleave
Journal:  Pharm Res       Date:  2020-01-21       Impact factor: 4.200

Review 8.  Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma.

Authors:  Mihaela Aldea; Ioan Alexandru Florian; Gabriel Kacso; Lucian Craciun; Sanda Boca; Olga Soritau; Ioan Stefan Florian
Journal:  Pharm Res       Date:  2016-05-26       Impact factor: 4.200

Review 9.  Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.

Authors:  K Laxmi Swetha; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 10.  Modifying the tumor microenvironment using nanoparticle therapeutics.

Authors:  Aniruddha Roy; Shyh-Dar Li
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.